Literature DB >> 9065997

Emergency oral anticoagulant reversal: the relative efficacy of infusions of fresh frozen plasma and clotting factor concentrate on correction of the coagulopathy.

M Makris1, M Greaves, W S Phillips, S Kitchen, F R Rosendaal, E F Preston.   

Abstract

Haemorrhage, including intracranial bleeding, is a common, potentially lethal complication of warfarin therapy and rapid and complete reversal of anticoagulation may be life-saving. Fresh frozen plasma (FFP) and vitamin K are most frequently administered. Because of the variable content of vitamin K-dependent clotting factors in FFP, and the effects of dilution, the efficacy of this approach is open to doubt. We have therefore compared the effects of FFP and clotting factor concentrates on the INRs and clotting factor levels of orally anticoagulated subjects requiring rapid correction of their haemostatic defect. In many, the pre-treatment INR was considered to be dangerously above the target therapeutic range. In the 12 patients given FFP, the INR did not completely correct (range 1.6-3.8, mean 2.3) indicating an ongoing anticoagulated state in all. In contrast, the INR in 29 subjects given clotting factor concentrates was completely corrected in 28 (range 0.9-3.8, mean 1.3). Following treatment, marked differences were observed in clotting factor IX levels between the two groups. The median factor IX level was 19 u/dl (range 10-63) following FFP infusion and 68.5 u/dl (range 31-111) following concentrate. In FFP treated patients, poorer responses were also observed for each of the other vitamin K-dependent clotting factors but these were less marked than for factor IX, which was present in low concentrations in some batches of FFP. Thus, haemostatically effective levels of factor IX cannot be achieved, in most instances, by the conventional use of FFP in patients requiring reversal of their anticoagulant therapy. Clotting factor concentrates are the only effective option where complete and immediate correction of the coagulation defect is indicated in orally anticoagulated patients with life or limb-threatening haemorrhage.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9065997

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  60 in total

Review 1.  Practical issues with vitamin K antagonists: elevated INRs, low time-in-therapeutic range, and warfarin failure.

Authors:  Andrea Lee; Mark Crowther
Journal:  J Thromb Thrombolysis       Date:  2011-04       Impact factor: 2.300

Review 2.  Prothrombin complex concentrates: an update.

Authors:  Massimo Franchini; Giuseppe Lippi
Journal:  Blood Transfus       Date:  2010-07       Impact factor: 3.443

3.  Challenges and controversies in the medical management of primary and antithrombotic-related intracerebral hemorrhage.

Authors:  Michael Moussouttas
Journal:  Ther Adv Neurol Disord       Date:  2012-01       Impact factor: 6.570

4.  Prothrombin complex concentrates utility for warfarin-associated hemorrhage.

Authors:  Secgin Soyuncu; Savas Aslan; Halil Mutlu; Firat Bektas
Journal:  Int J Clin Exp Med       Date:  2015-02-15

5.  Recommendations for the use of antithrombin concentrates and prothrombin complex concentrates.

Authors:  Giancarlo Liumbruno; Francesco Bennardello; Angela Lattanzio; Pierluigi Piccoli; Gina Rossetti
Journal:  Blood Transfus       Date:  2009-10       Impact factor: 3.443

6.  [Bleeding complications due to anticoagulatoric therapy].

Authors:  R Mahnel; S Bassus; C M Kirchmaier
Journal:  Internist (Berl)       Date:  2009-12       Impact factor: 0.743

7.  Three or four factor prothrombin complex concentrate for emergency anticoagulation reversal?

Authors:  Mike Makris; Joost J Van Veen
Journal:  Blood Transfus       Date:  2011-01-13       Impact factor: 3.443

8.  Intracerebral hemorrhage: clinical overview and pathophysiologic concepts.

Authors:  Fred Rincon; Stephan A Mayer
Journal:  Transl Stroke Res       Date:  2012-04-21       Impact factor: 6.829

Review 9.  Prothrombin complex concentrates for oral anticoagulant therapy-related intracranial hemorrhage: a review of the literature.

Authors:  Eric M Bershad; Jose I Suarez
Journal:  Neurocrit Care       Date:  2010-06       Impact factor: 3.210

Review 10.  [Intracerebral hemorrhage related to anticoagulant therapy].

Authors:  H B Huttner; E Jüttler; A Hug; M Köhrmann; P D Schellinger; T Steiner
Journal:  Nervenarzt       Date:  2006-06       Impact factor: 1.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.